Member Info for Peterrr

Manufacturers, Singapore, Thailand, India. Consumption Singapore, Australia, maybe New Zealand, couple in Europe. Could probably get Japan if they can wrap their heads around the red tape.

On that basis if POLB runs out of cash probably a trigger event allowing CF to retain control of the only thing of potential value.

Thanks Deco. I thought that would have required some disclosure but obviously not.

The patents say it is owned by Poolbeg.

A shortage of capital is an ongoing problem which may get a leg up from Mansion House Compact 2. Would need some appetite for risk though.

https://www.professionalpensions.com/news/4412547/mansion-house-compact-ii-draft-circulated-tense-negotiations

What do you mean? I thought they had already reported selling some. As a realised profit, probably justification for the next round of zero p option grants to management for performance above and beyond.

The cynic in me says they paid for the slot especially as it reads like they wrote it and they paid for others like the Pharma Newsletter for similar. But I guess even a change of promotion is worth a punt if it widens the audience and doesn’t eat too much into the limited remaining cash.

Plenty already moved over. This is low hanging fruit but everyone is doing it so no real competitive advantage in pricing subsequent contracts.

Onego has a very large pilot plant in production and before the US build a fully funded mid size scale up plant which has to be constructed in Finland because of the associated EU grant. So arguably they are ahead of Solar Foods. But yes expect some dilution but probably an uplift on the carrying value irrespective. But note they could also use contractors for supply as they have hired roles specifically for technology transfer in the US.

For once I partially agree with Oak. But Revolut markup+ buyback means quite ordinary performance from most of the portfolio. As for ICEYE, which I like, has newsflow which they are very proactive with, but does not equate to profit as most of it is marketing while they fine tune their product offerings.

Unreported Countac. Get the clinical trials database showing results instead of nothing for years and some published credibility can be attached to it and quoted. Management paying for the conference junket for the doctors but not getting it published, why bother.

Show me the actual medical results to date. They report next year per the trial database and most still not started. There are no sales in the US and probably Europe as their own product has been provided for free. For something on the market for 6 years, poorly managed. When is the NICE review, Dec26 at the earliest now. Possibly traders buying up so maybe a pump pre results.

I wouldn’t worry about the feel good pronouncements, about half my portfolio feel the need to do similar, irrespective of how they actually conduct business. Capita is no different. I would, however prefer a bit more slash and burn instead of the chipping away with AI tools at internal inefficiencies and also prefer the consolidation didn’t happen at all. You could do a lot worse than AH, at least he knows what needs doing and has a game plan, even if the under performers keep over promising and somehow still under performing. Other units remain focused, profitable and competitive.

JJ mixed messages on LL completion, but the latest jobs listing for the Operating Team requires a start in October with a go live at the end of the year. Certainly won’t be any earlier.

Sorry can’t see how Intuitive Financial strength and that it could buy CREO with loose change has any impact on anything. More realist than glass half empty. Trials complete about the same time money gets tight, at which time these directors would sell their grandma if it meant not reducing their compensation.

CREO has not completed any trials , god knows how they expected to convince anyone to buy without the evidence, instead prioritising management salaries. No excuses now, a couple of trials underway from the many registered, unfortunately still a waiting game. But I wouldn’t be surprised if they sold off the rest of Europe in the meantime.

25% very unlikely as the last major round from the EU sounded like a grant but was on a CNote just like ANIC’s .

Analysts have been wrong every year since 2016, why would they be correct now? They are relying on the same data sources for their projections. And yes expect a cap raise post consolidation if YTD performance continues as is, because they are running out of stuff to sell and tapering the cost saving offshoring as lots of the remaining contracts need boots on the ground in the UK. Client satisfaction is high, margins are too thin.

Be careful this isn’t a false dawn. Implementation of AI and legislative pension changes is a key profit driver. Once implemented the client wants a share of the cost savings long term. So you are still dependent on old school project work to fill larger profit gaps. But maybe they are locked in now due to the complexity of what has been built, so swings and roundabouts. Pensions has always been profitable since pre Lewis, but the rest may be worth net zero when everyone else’s losses are factored in.

Still a long way from profitable in many contracts and increasing pressure in a race to the bottom in many cash strapped renewals. Heavy reliance in supplemental value add work which may or may not eventuate. Clients want to see cost savings from AI as well as service perfection and can’t accept only one. Divisional leadership will change again soon but really the cull needs to happen on the still entrenched management wall which is adept at looking useful, whilst making profitability impossible. Same as my posts the last few years really. Plenty senior unhappy about the consolidation, given there are virtually no success stories, but looks like a done deal.